Global Viral Vectors and Plasmid DNA Manufacturing Market Report, 2018-2030 with Presentation of Over 430 Gene Therapy Candidates

World News: . []

Dublin, June 14, 2018 (GLOBE NEWSWIRE) -- The report has been added to offering. The Viral Vectors and Plasmid DNA Manufacturing Market (2nd Edition), 2018-2030 report offers a comprehensive study of the current scenario of manufacturing of viral and non-viral vectors that are primarily used for the development of gene therapies and T-cell therapies. The study features an in-depth analysis, highlighting the capabilities of a diverse set of players, covering both contract manufacturers and companies with in-house capabilities.

Genetically modified therapies have emerged as a promising treatment option for various diseases (primarily ones that currently have no cure), including cancers, inherited disorders and certain viral infections. These therapies have demonstrated the potential to treat chronic indications, such as Alzheimer's disease, Parkinson's disease and rheumatoid arthritis, as well. Gene therapies, and other therapies that require genetic modification, involve the introduction of therapeutic DNA / gene of interest into a patient's body / cells. This process is accomplished by the use of vectors. Over the last few decades, various viral and non-viral vectors have been developed, optimized and standardized for this purpose.

Currently, the most popular viral vectors, on the basis of their use in active clinical trials, are those based on AAV, adenovirus, lentivirus and retrovirus. On the other hand, among non-viral gene delivery tools, plasmid DNA has emerged as the preferred option. Plasmid DNA is also used in the development and production of viral vectors and DNA vaccines. Recent advances have led to the emergence of several other innovative viral / non-viral gene delivery approaches that are being utilized for development of various therapies that require gene modification. Overall, eleven genetically modified therapies have been approved so far; these are (in the order of approval, most recent first) LUXTURNA, YESCARTA, Kymriah, INVOSSA, Zalmoxis, Strimvelis, Imlygic, Neovasculagen, Rexin-G, Oncorine and Gendicine. Amongst these, YESCARTA and Kymriah are T-cell based gene therapies that were recently approved by the FDA, in October 2017 and August 2017, respectively.

In addition, over 430 gene therapy candidates are presently in different stages of clinical development, for which over 500 clinical studies are currently underway in various regions across the globe. The growing number of gene therapy candidates, coupled with their rapid progression through various phases of clinical development, is expected to continue to create an increasing demand for vectors.

1. PREFACE1.1. Scope of the Report1.2. Research Methodology1.3. Chapter Outlines2. EXECUTIVE SUMMARY3. INTRODUCTION3.1. Chapter Overview3.2. Viral and Non-Viral Methods of Gene Transfer3.3. Viral Vectors for Genetically Modified Therapies3.4. Type of Viral Vectors3.4.1. Adeno-associated Viral Vectors3.4.2. Adenoviral Vectors3.4.3. Lentiviral Vectors3.4.4. Retroviral Vectors3.4.5. Other Viral Vectors3.4.5.1. Alphavirus3.4.5.2. Foamy Virus3.4.5.3. Herpes Simplex Virus3.4.5.4. Sendai Virus3.4.5.5. Simian Virus3.4.5.6. Vaccinia Virus3.5. Types of Non-Viral Vectors3.5.1. Plasmid DNA3.5.2. Liposomes, Lipoplexes and Polyplexes3.5.3. Oligonucleotides3.5.4. Other Non-Viral Vectors3.5.5. Methods of Gene Delivery using Non-Viral Vectors: Methods of Transfection3.5.5.1. Biolistic Methods3.5.5.2. Electroporation3.5.5.3. Receptor Mediated Gene Delivery3.5.5.4. Gene Activated Matrix (GAM)3.6. Applications of Viral and Non-Viral Vectors3.6.1. Type of Therapy3.6.1.1. Gene Therapy3.6.1.2. Vaccinology3.6.2. Current Trends in Vector Development / Manufacturing3.6.2.1. Vector Engineering: Synthetic and Next Generation Vectors3.6.2.2. Cargo Engineering4. VIRAL VECTOR MANUFACTURERS: COMPETITIVE LANDSCAPE4.1. Chapter Overview4.2. Viral Vectors Manufacturers: Overall Market Landscape4.2.1. Distribution by Year of Establishment4.2.2. Distribution by Location of Manufacturing Facility4.2.3. Distribution by Type of Organization4.2.4. Distribution by Purpose of Production4.2.5. Distribution by Type of Vector4.2.6. Distribution by Scale of Production5. PLASMID DNA MANUFACTURERS: COMPETITIVE LANDSCAPE5.1. Chapter Overview5.2. Plasmid DNA Manufacturers: Overall Market Landscape5.2.1. Distribution by Year of Establishment5.2.2. Distribution by Location of Manufacturing Facility5.2.3. Distribution by Type of Organization5.2.4. Distribution by Purpose of Production5.2.5. Distribution by Scale of Production6. VIRAL VECTORS AND PLASMID DNA MANUFACTURING IN NORTH AMERICA6.1. Chapter Overview6.2. Aldevron6.3. BioReliance / SAFC Commercial (Merck KGaA)6.4. bluebird bio6.5. Brammer Bio6.6. FUJIFILM Diosynth Biotechnologies6.7. MassBiologics6.8. Novasep6.9. Spark Therapeutics6.10. Vigene Biosciences7. VIRAL VECTORS AND PLASMID DNA MANUFACTURING IN EUROPE7.1. Chapter Overview7.2. Biovian7.3. Cell and Gene Therapy Catapult7.4. Cobra Biologics7.5. FinVector7.6. Kaneka Eurogentec7.7. Lonza7.8. MolMed7.9. Oxford BioMedica7.10. Richter-Helm7.11. Sanofi (CEPiA, Sanofi Pasteur, Genzyme)7.12. uniQure7.13. VIVEbiotech8. VIRAL VECTORS AND PLASMID DNA MANUFACTURING IN ASIA-PACIFIC8.1. Chapter Overview8.2. Wuxi AppTec8.3. Other Key Players9. EMERGING VECTORS9.1. Chapter Overview9.1.1. Alphavirus Based Vectors9.1.2. Bifidobacterium longum (B. longum) Based Vectors9.1.3. Cytomegalovirus (CMV) Based Vectors9.1.4. Listeria Monocytogenes Based Vectors9.1.5. Minicircle DNA Based Vectors9.1.6. Myxoma Virus Based Vectors9.1.7. Self-Complementary Vectors9.1.8. Sendai Virus Based Vectors9.1.9. Sleeping Beauty Transposons10. RECENT COLLABORATIONS AND PARTNERSHIPS10.1. Chapter Overview10.2. Partnership Models10.3. Viral Vectors and Plasmid DNA Manufacturing: Recent Collaborations and Partnerships10.4. Other Collaborations11. KEY INSIGHTS11.1. Chapter Overview11.2. Viral Vectors and Plasmid DNA Manufacturers: Competitive Landscape by Vector Type, Scale of Operation and Purpose of Manufacturing11.3. Viral Vectors and Plasmid DNA Manufacturers: Logo Landscape by Vector Type and Size of the Company11.4. Viral Vectors and Plasmid DNA Manufacturers: Prominent Geographical Hubs by Type of Manufacturer11.4.1. Contract Manufacturers11.4.2. In-House Manufacturers11.5. Viral Vectors and Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facility and Type of Vector11.5.1. AAV Vector Manufacturers11.5.2. Adenoviral Vector Manufactures11.5.3. Lentiviral Vector Manufactures11.5.4. Retroviral Vector Manufactures11.5.5. Plasmid DNA Manufactures12. VIRAL VECTORS AND PLASMID DNA: COST PRICE ANALYSIS12.1. Chapter Overview12.2. Viral Vectors and Plasmid DNA Based Therapies (Genetically Modified Therapies): Factors Contributing to Higher Price Tags12.3. Viral Vectors and Plasmid DNA Prices12.3.1. Based on Expert Opinions12.3.2. Based on Manufacturing Cost12.3.2.1. Based on Technology Used12.3.2.2. Based on Scale of Manufacturing12.3.2.3. Based on Client Type12.3.3. Price Points on Different Types of Vectors12.4. Concluding Remarks13. CAPACITY ANALYSIS13.1. Chapter Overview13.2. Key Assumptions and Methodology13.3. Viral Vectors Manufacturing: Installed Global Capacity13.4. Plasmid DNA Manufacturing: Installed Global Capacity13.5. Viral Vectors and Plasmid DNA Manufacturing: Overall Installed Global Capacity14. MARKET SIZING AND OPPORTUNITY ANALYSIS14.1. Chapter Overview14.2. Scope of the Forecast14.3. Forecast Methodology14.4. Input Tables and Key Assumptions14.5. Overall Viral Vectors and Plasmid DNA Manufacturing Market, 2018-203014.5.1. Viral Vectors and Plasmid DNA Manufacturing Market, 2018-2030: Distribution by Vector Type (AAV, Adenoviral, Lentiviral, Retroviral, Plasmid DNA, Other Viral Vectors)14.5.2. Viral Vectors and Plasmid DNA Manufacturing Market, 2018-2030: Distribution by Application (Gene Therapy / T-cell Therapy)14.5.3. Viral Vectors and Plasmid DNA Manufacturing Market, 2018-2030: Distribution by Therapeutic Area (Oncology, Inflammation & Immunology, Ophthalmology, Metabolic Disorders, Cardiovascular Disorders, Others)14.5.4. Viral Vectors and Plasmid DNA Manufacturing Market, 2018-2030: Distribution by Scale of Operation (Clinical / Commercial)14.5.5. Viral Vectors and Plasmid DNA Manufacturing Market, 2018-2030: Distribution by Geography (North America, Europe, Asia-Pacific, RoW)14.6. Opportunity from Commercial Products14.6.1. AAV Vectors14.6.2. Adenoviral Vectors14.6.3. Lentiviral Vectors14.6.4. Retroviral Vectors14.6.5. Plasmid DNA14.6.6. Other Viral Vectors14.7. Opportunity from Clinical Products14.7.1. AAV Vectors14.7.2. Adenoviral Vectors14.7.3. Lentiviral Vectors14.7.4. Retroviral Vectors14.7.5. Plasmid DNA14.7.6. Other Viral Vectors15. DRIVERS AND CHALLENGES15.1. Chapter Overview15.2. Viral Vectors and Plasmid DNA: Drivers and Challenges15.2.1. AAV Vectors15.2.2. Adenoviral Vectors15.2.3. Lentiviral Vectors15.2.4. Retroviral Vectors15.2.5. Plasmid DNA15.3. Additional Information16. SURVEY ANALYSIS16.1. Chapter Overview16.2. Seniority Level of Respondents16.3. Type of Vector16.4. Scale of Production16.5. Vector Stabilization Technology16.6. In-house / Contract Operations17. CONCLUSION17.1. Increasing Efforts Related to Development of Advanced Therapy Candidates that Require Genetic Manipulation have Led to a Rise in the Demand for Vectors17.2. Manufacturing Efforts in this Domain Feature the involvement of Several Industry Players and Academic Institutes; Many Startups have also been Established in the Recent Past17.3. Given Regulatory Stringencies and Exorbitant Costs Associated with Developing In-House Facilities, Outsourcing Has Emerged as a Reliable Option for Vector Manufacturing17.4. Manufacturers Have Established their Presence Across Different Regions; the US and EU have Emerged as Key Hubs17.5. Several Efforts to Develop Innovative Technology Platforms are Underway, and are Expected to Drive the Production of Efficient, Safe and Stable Vectors17.6. Novel Viral and Bacterial Strains are Being Investigated as Vectors for use in Genetically Modified Therapies / Vaccines17.7. The Partnership Activity in this Domain is on the Rise as Companies Actively Collaborate to Develop Innovative Manufacturing Technology Platforms17.8. Driven by a Rapidly Evolving Pipeline of Therapies, the Market is Anticipated to Grow at an Accelerated Pace over the Coming Decade18. EXECUTIVE INSIGHTS18. Executive Insights18.1. Chapter Overview18.2. Amsterdam BioTherapeutics Unit (AmBTU)18.2.1. Overview of the Organization18.2.2. Interview Transcript: Joost van den Berg, Director18.3. ACGT18.3.1. Overview of the Organization18.3.2. Interview Transcript: Semyon Rubinchik, Scientific Director18.4. CEVEC Pharmaceuticals18.4.1. Overview of the Organization18.4.2. Interview Transcript: Nicole Faust, Chief Executive Officer & Chief Scientific Officer18.5. Clean Cells18.5.1. Overview of the Organization18.5.2. Interview Transcript: Laurent Ciavatti, Business Development Manager, Olivier Boisteau, President / Co-Founder and Xavier Leclerc, Head of Gene Therapy18.6. CJ PARTNERS18.6.1. Overview of the Organization18.6.2. Interview Transcript: Interview Transcript, Colin Lee Novick, Managing Director18.7. Delphi Genetics18.7.1. Overview of the Organization18.7.2. Interview Transcript: Cedric Szpirer, Executive & Scientific Director18.8. GEG Tech18.8.1. Overview of the Organization18.8.2. Interview Transcript: Nicolas Grandchamp, R&D Leader18.9. MGH Viral Vector Development Facility, Massachusetts General Hospital18.9.1. Overview of the Organization18.9.2. Interview Transcript: Bakhos A Tannous, Director18.10. Novasep18.10.1. Overview of the Organization18.10.2. Interview Transcript: Alain Lamproye, President of Biopharma Business Unit18.11. Richter-Helm18.11.1. Overview of the Organization18.11.2. Interview Transcript: Astrid Brammer, Senior Manager Business Development18.12. Plasmid Factory18.12.1. Overview of the Organization18.12.2. Interview Transcript: Marco Schmeer, Project Manager and Tatjana Buchholz, Marketing Manager18.13. Vigene Biosciences18.13.1. Overview of the Organization18.13.2. Interview Transcript: Jeffrey Hung, Chief Commercial Officer18.14. Waisman Biomanufacturing18.14.1. Overview of the Organization18.14.2. Interview Transcript: Brian M Dattilo, Business Development Manager

For more information about this report visit

Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Genomics

More news and information about Research and Markets

Published By:

Globe Newswire: 11:06 GMT Thursday 14th June 2018

Published: .

Search for other references to "global" on SPi News

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
Privacy Policy | Terms and Conditions | Contact Us

Advertising on SPi News: Information For Advertisers